Fluticasone propionate/salmeterol (Advair Diskus) vs indacaterol maleate / mometasone furoate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline

Fluticasone propionate/salmeterol (Advair Diskus)

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Partial signal

NCT00920959 · Phase 3 · completed

This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)

Result source: NCT00920959

indacaterol maleate / mometasone furoate

Marketed by Novartis

Phase 3 in Asthma
Partial signal

NCT00557440 · Phase 2 · completed

The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.

Next expected readout: February 2028 · NCT05562466 (registry estimate)

Reported efficacy

Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016) (met)

Result source: NCT02554786

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFluticasone propionate/​salmeterol (Advair Diskus)indacaterol maleate /​ mometasone furoate
Severe exacerbations, annualised rate2.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT00452348—Trial running · NCT05562466
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
0.1 vs -0.1+0.2 vs placebowk 0.14 · n 36NCT00557440
ACQ-5, change—Not posted · NCT00920959—Trial running · NCT05562466
OCS dose reduction—Not posted · NCT00920959—Trial running · NCT05562466

Severe exacerbations, annualised rate

Fluticasone propionate/​salmeterol (Advair Diskus)
2.6 vs 2.7vs FP DISKUS250/50 mcg BID · wk 52 · n 310NCT00452348
indacaterol maleate /​ mometasone furoate
—Trial running · NCT05562466

Trough FEV1, change

Fluticasone propionate/​salmeterol (Advair Diskus)
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs -0.1 wk 0.14 · n 36 · Phase 2 · primary NCT00557440
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
indacaterol maleate /​ mometasone furoate
0.1 vs -0.1+0.2 vs placebowk 0.14 · n 36NCT00557440

ACQ-5, change

Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959
indacaterol maleate /​ mometasone furoate
—Trial running · NCT05562466

OCS dose reduction

Fluticasone propionate/​salmeterol (Advair Diskus)
—Not posted · NCT00920959
indacaterol maleate /​ mometasone furoate
—Trial running · NCT05562466
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fluticasone propionate/salmeterol (Advair Diskus): 4 of 4 rows · indacaterol maleate / mometasone furoate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone propionate/​salmeterol (Advair Diskus)indacaterol maleate /​ mometasone furoate
Dropout rate
0.2%a
NCT01475721 · Phase 4
show 14 more results
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
7.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—
NCT00557440 · Phase 2 · combination · Asthma · phase 2
show 1 more result
0%
NCT00605306 · Phase 2 · Asthma · phase 2
Discontinued due to AEs
—a
NCT01475721 · Phase 4
show 14 more results
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
0.7%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
—100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
—
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
—
NCT00557440 · Phase 2 · combination · Asthma · phase 2
show 1 more result
0%
NCT00605306 · Phase 2 · Asthma · phase 2
Serious AEs
2.3%a
NCT01475721 · Phase 4
show 14 more results
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
4.4%100/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0%250/50 mcg BID
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0%100mcg/50mcg
NCT00927758 · Phase 2 · registry result, not featured evidence
0%
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
0%
NCT00557440 · Phase 2 · combination · Asthma · phase 2
show 1 more result
0%
NCT00605306 · Phase 2 · Asthma · phase 2
Most frequent reported AEs
a
asthma 0.8%
NCT01475721 · Phase 4
show 14 more results
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/31.25/25 mcg
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
250/50 mcg BID
headache 11%
hypertension 6.1%
blood pressure increased 0%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
250/50 mcg BID
headache 12.2%
hypertension 4.9%
blood pressure increased 3.7%
NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100mcg/50mcg
cough 5%
upper respiratory infection 5%
viral upper respiratory infection 5%
NCT00927758 · Phase 2 · registry result, not featured evidence
headache 5.6% (placebo 5.4%)
NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2
headache 5.6% (placebo 5.4%)
NCT00557440 · Phase 2 · combination · Asthma · phase 2
show 1 more result
cough 35.7% (placebo 14.3%)
headache 35.7% (placebo 14.3%)
bronchitis 14.3% (placebo 0%)
NCT00605306 · Phase 2 · Asthma · phase 2

Notes

  1. aPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone propionate/salmeterol (Advair Diskus)

Asthma Exacerbation Occurrence 8.2% (n=5834) vs 10.2% (n=5845) Fluticasone Propionate @ 26wk
event count · % of participants
NCT01475721 · Phase 4 · converted to % from 480 Participants as posted
Morning PEF 27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
absolute change · L
NCT00452348 · Phase 4 · registry result, not featured evidence
show 2 more results
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 2.63 vs 2.73 FP DISKUS per year @ 52wk250/50 mcg BID
event rate · per year
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 Max Fall -9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BID
absolute value · percentage points
NCT00118716 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence
Evening PEF 10.8 vs 7.6 FP L/min @ 4wk100/50mcg BID
absolute change · L/min
NCT00118716 · Phase 4 · registry result, not featured evidence
Rescue-free 59.4 vs 54.7 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
Asthma Symptom Free 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 22 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair Diskus)'s landscape · indacaterol maleate / mometasone furoate's landscape